Oncotarget

Research Papers:

Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells

Andreas Ritter, Alexandra Friemel, Nina-Naomi Kreis, Frank Louwen and Juping Yuan _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:84271-84285. https://doi.org/10.18632/oncotarget.12482

Metrics: PDF 1430 views  |   HTML 4633 views  |   ?  


Abstract

Andreas Ritter1, Alexandra Friemel1, Nina-Naomi Kreis1, Frank Louwen1,Juping Yuan1

1Department of Gynecology and Obstetrics, School of Medicine, J. W. Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany

Correspondence to:

Juping Yuan, email: yuan@em.uni-frankfurt.de

Keywords: adipose tissue-derived stem cell, Plk1 inhibitors, mitotic arrest, apoptosis, senescence

Received: August 05, 2016     Accepted: September 29, 2016     Published: October 05, 2016

ABSTRACT

Polo-like kinase 1 (Plk1) has been established as one of the most promising targets for molecular anticancer intervention. In fact, various Plk1 inhibitors have been identified and characterized. While the data derived from the bench are prospective, the clinical outcomes are less encouraging by showing modest efficacy. One of the explanations for this discrepancy could be unintendedly targeting of non-malignant cells by Plk1 inhibitors. In this work, we have addressed the effect of Plk1 inhibition in adipose tissue-derived mesenchymal stem cells (ASCs). We show that both visceral and subcutaneous ASCs display monopolar spindles, reduced viability and strong apoptosis induction upon treatment with BI 2536 and BI 6727, the Plk1 kinase domain inhibitors, and with Poloxin, the regulatory Polo-box domain inhibitor. While Poloxin triggers quickly apoptosis, BI 2536 and BI 6727 result in mitotic arrest in ASCs. Importantly, survived ASCs exhibit DNA damage and a pronounced senescent phenotype. In addition, Plk1 inhibition impairs ASCs’ motility and homing ability. These results show that Plk1 inhibitors target slowly proliferating ASCs, an important population of anti-inflammation and immune modulation. The toxic effects on primary cells like ASCs could be partially responsible for the reported moderate antitumor activity in patients treated with Plk1 inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12482